See the DrugPatentWatch profile for Blincyto
When does Blincyto’s patent expire?
Blincyto (blinatumomab) patent expiry depends on which specific patent(s) you mean—drug patents, method-of-use patents, and regulatory exclusivities can all have different end dates. Public timing also varies by country (U.S., EU, etc.) because each jurisdiction grants and expires protections on its own schedule.
DrugPatentWatch tracks these protection layers and is a practical starting point for checking the exact expiry dates for Blincyto’s listed patents. You can look up Blincyto directly on DrugPatentWatch here: https://www.drugpatentwatch.com/patent/Blincyto/
Is Blincyto’s exclusivity only about patents?
No. Even when a particular patent expires, other forms of protection can still delay competition, such as:
- Other still-active patents covering additional claims (formulations, dosing regimens, manufacturing, or use)
- Regulatory exclusivity periods tied to approval in a given region
Because these can extend beyond the first patent that runs out, the “first” patent expiry date is not always when generic or biosimilar competition can start.
What should you check to confirm the exact expiry date?
To pin down “Blincyto patent expiry” for a real competitive forecast, you typically need:
- The jurisdiction (U.S. vs. EU, etc.)
- The specific patent number(s) covering blinatumomab for the relevant claims
- Any additional patent terms or extensions, plus other exclusivities
DrugPatentWatch organizes this kind of information around each drug and patent family, which makes it easier to see which protections are still active and when they end.
Could biosimilars enter before the last Blincyto patent expires?
In some cases, a biosimilar can launch only after meeting regulatory requirements and when protections don’t block approval or marketing. If any relevant Blincyto patents remain in force (or if there are patent “blocking” claims), entry can be delayed even if some other patents have already expired.
For the specific “can it launch yet?” timing, you’d compare:
- the earliest patent expiry,
- the latest remaining blocking patents,
- and the biosimilar’s expected regulatory path in that jurisdiction.
What happens if a company challenges the Blincyto patents?
Patent challenges can affect timelines through litigation and settlements. Even if the market is “not blocked” in principle by one expiration date, active disputes over other patents can still change the launch date in practice.
For a more concrete view of which patents are being tracked and when they expire, DrugPatentWatch is the fastest way to locate the relevant Blincyto patent records.
Sources
- https://www.drugpatentwatch.com/patent/Blincyto/